IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$472.35 USD
+3.17 (0.68%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$472.35 USD
+3.17 (0.68%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
4 Large-Cap Medical Device Stocks to Buy Amid Political Woes
by Zacks Equity Research
Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.
Mazor Robotics Hits 52-Week High Through Medtronic Alliance
by Zacks Equity Research
Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.
GNC Holdings Gains on New GNC Strength Amid Soft Revenues
by Zacks Equity Research
GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.
3 MedTech Stocks Set to Rally in the Second Half
by Zacks Equity Research
The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.
The Cooper Companies (COO) Beats Earnings Estimates in Q3
by Zacks Equity Research
The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.
Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm
by Zacks Equity Research
Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.
Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm
by Zacks Equity Research
Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.
BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)
by Zacks Equity Research
BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.
Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates
by Zacks Equity Research
Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.
VWR Awaits Merger Closure, Stock Upside Potential Limited
by Zacks Equity Research
VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.
Cooper (COO) Poised to Grow on Specialty Lenses Prospects
by Zacks Equity Research
Cooper's (COO) strong sales growth will continue to be aided by its leading position in the markets of specialty lenses.
Thermo Fisher Acquires Patheon, Boosts Laboratory Products
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.
Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now
by Zacks Equity Research
Lantheus Holdings (LNTH) banks on DEFINITY and TechneLite sales for growth. The company's focus on global expansion is also encouraging.
Intuitive Surgical (ISRG) Well Poised on Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.
LabCorp Grows on Solid Diagnostics, Currency Woes a Drag
by Zacks Equity Research
Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.
Medtronic (MDT) Sees a Mixed Q1, New Products Bode Well
by Zacks Equity Research
Despite mixed results in Q1, Medtronic (MDT) displayed balanced growth with strength in three of its major business segments.
PetMed Express Focuses on Advertising, Competition Rife
by Zacks Equity Research
PetMed Express (PETS) focuses on advertising to boost new order sales is striving to implement several strategies to revitalize its top line.
Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.
LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
by Zacks Equity Research
LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.
NxStage System One Gets FDA Nod for Solo Home Hemodialysis
by Zacks Equity Research
The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.
Veeva (VEEV) to Gain Through Subscription Revenue Focus
by Zacks Equity Research
Veeva's (VEEV) strong sales growth will continue to be aided by focus on subscription revenue, better pricing and product innovation. However, higher costs remain a concern.
Hill-Rom (HRC) Stock Down With Dull Patient Support Systems
by Zacks Equity Research
Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.
LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval
by Zacks Equity Research
The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.